Payment overview · 2025
General Payments
$320,061.00
364 reported records · 12 companies
Healthcare provider profile · identity verified
Sunil Kapur, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BOSTON, MA · NPI 1144458399
Verified facts
What the public records show
CMS Open Payments records show Sunil Kapur, MD received $320,061.00 in general payments during 2025 across 364 reported records.
Boston Scientific Corporation accounted for 61.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $195,751.70 | 61.2% | 190 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35,241.99 | 11.0% | 45 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $32,915.91 | 10.3% | 55 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21,254.81 | 6.6% | 38 | 2025 |
| Elutia, Inc. | Unresolved — no canonical attribution shown | $14,167.10 | 4.4% | 6 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $8,047.83 | 2.5% | 6 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $7,542.50 | 2.4% | 5 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $4,662.47 | 1.5% | 11 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $202.90 | 0.1% | 3 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $158.82 | 0.1% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $91.30 | 0.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.67 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $186,816.89 | 126 |
| Consulting Fee | $63,599.88 | 34 |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,816.28 | 9 |
| Travel and Lodging | $22,832.96 | 83 |
| Honoraria | $13,931.00 | 3 |
| Food and Beverage | $7,063.99 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $72,187.50 | 83 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $36,051.24 | 22 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $32,040.23 | 20 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $22,386.66 | 25 | 2025 |
Source payment records
|
|||||
| VersaCross Large Access Solution Normalized: versacross large access solution |
Device | Boston Scientific Corporation | $14,571.60 | 4 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $14,569.63 | 20 | 2025 |
Source payment records
|
|||||
| ECM Patch,Pouch Normalized: ecm patch pouch |
Device | Elutia, Inc. | $14,167.10 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $9,431.97 | 9 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $8,576.34 | 12 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $7,874.44 | 3 | 2025 |
Source payment records
|
|||||
| Ultra ICE Plus Normalized: ultra ice plus |
Device | Boston Scientific Corporation | $5,756.60 | 3 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $4,212.97 | 10 | 2025 |
Source payment records
|
|||||
| ACCENT Normalized: accent |
Device | Abbott Laboratories | $4,056.25 | 3 | 2025 |
Source payment records
|
|||||
| FlexTract Normalized: flextract |
Device | Merit Medical Systems Inc | $3,771.25 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $3,125.00 | 5 | 2025 |
Source payment records
|
|||||
| Clinical Trial Product Normalized: clinical trial product |
Device | Boston Scientific Corporation | $2,195.21 | 3 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $1,562.50 | 1 | 2025 |
Source payment records
|
|||||
| LithoVue Empower Normalized: lithovue empower |
Device | Boston Scientific Corporation | $1,319.60 | 8 | 2025 |
Source payment records
|
|||||
| INGEVITY MRI Normalized: ingevity mri |
Device | Boston Scientific Corporation | $1,209.83 | 5 | 2025 |
Source payment records
|
|||||
| Selectra Normalized: selectra |
Device | BIOTRONIK INC. | $1,155.40 | 4 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $1,135.79 | 5 | 2025 |
Source payment records
|
|||||
| ICEfx Cryoablation System Normalized: icefx cryoablation system |
Device | Boston Scientific Corporation | $1,073.42 | 4 | 2025 |
Source payment records
|
|||||
| Solia Normalized: solia |
Device | BIOTRONIK INC. | $1,052.08 | 3 | 2025 |
Source payment records
|
|||||
| VersaCross RF Wire Normalized: versacross rf wire |
Device | Boston Scientific Corporation | $657.37 | 3 | 2025 |
Source payment records
|
|||||
| Thermocool SF Normalized: thermocool sf |
Device | Biosense Webster, Inc. | $449.50 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $354.90 | 9 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $187.79 | 2 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $173.39 | 3 | 2025 |
Source payment records
|
|||||
| TACTICATH ABLATION CATHETER, SENSOR ENABLED Normalized: tacticath ablation catheter sensor enabled |
Device | Abbott Laboratories | $168.53 | 2 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $158.82 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $156.86 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $155.27 | 2 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $62.80 | 3 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $61.34 | 2 | 2025 |
Source payment records
|
|||||
| TENDRIL Normalized: tendril |
Device | Abbott Laboratories | $47.73 | 2 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $46.09 | 2 | 2025 |
Source payment records
|
|||||
| EVERA MRI XT DR SURESCAN Normalized: evera mri xt dr surescan |
Device | Medtronic, Inc. | $33.53 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $6.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 22 | 11 |
| Eliquis | Apixaban | 18 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $320,061.00 · 364 records | Boston Scientific Corporation | ACCENT, AFFERA MAPPING SYSTEM, AMPLATZER AMULET, AMVIA EDGE, AURORA EV-ICD MRI SURESCAN, AVEIR, Acticor 7 VR-T DX, BIOMONITOR, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, Clinical Trial Product, ECM Patch,Pouch, EMBLEM MRI S-ICD, ENSITE, EVERA MRI XT DR SURESCAN, FARAPULSE, FlexTract, General - Brady, General - CRM_CRM, General - EP, General - Therapies, ICEfx Cryoablation System, IGT Devices Undivided, INGEVITY MRI, LM Undivided, LithoVue Empower, MICRA, MYNX CONTROL VENOUS, Optimizer, REPATHA, Selectra, Solia, TACTICATH ABLATION CATHETER, SENSOR ENABLED, TENDRIL, Thermocool SF, Ultra ICE Plus, VersaCross Large Access Solution, VersaCross RF Wire, WATCHMAN Access System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error